Federated Hermes’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Federated Hermes’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-144,002	Closed	-$3.41M	–	2356
2019 Q3	$3.41M	Buy	144,002 +34,436	+31%	+$1.02M	0.01%	867
2019 Q2	$3.29M	Sell	109,566 -165,947	-60%	-$3.8M	0.01%	915
2019 Q1	$6.17M	Buy	275,513 +93,433	+51%	+$2.01M	0.02%	719
2018 Q4	$3.31M	Buy	182,080 +178,504	+4,992%	+$2.8M	0.01%	851
2018 Q3	$65K	Buy	+3,576	New	+$42.4K	﹤0.01%	1709

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes's RARX Position: Q4 2019 in Review

Federated Hermes sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 144,002 shares — an estimated $3.41M sold.

Federated Hermes first reported a position in RARX in Q3 2018 and held it in 5 quarters. The position peaked at $6.17M in Q1 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Federated Hermes reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Federated Hermes sold 144,002 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $3.41M.
Federated Hermes first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
Federated Hermes's Ra Pharmaceuticals, Inc. Common Stock position peaked at $6.17M in Q1 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Federated Hermes's 13F filing for Q4 2019, filed 14 Feb 2020.